BMJ

Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group

7 Department of Medicine, Section of Rheumatology, University of Florence, Florence, Italy 8 Department of Internal Medicine and Rheumatology, Justus-Liebig-University of Giessen, Kerckhoff-Klinik, ...
BMJ

Osteoarthritis research priorities: a report from a EULAR ad hoc expert committee

3 Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany 4 Department of Rheumatology & Clinical Immunology, University Medical Center ...
BMJ

Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis

Background: Although disease-specific health status measures are available for ankylosing spondylitis (AS), no instrument exists for assessing quality of life (QoL) in the condition. Objective: To ...
BMJ

Modification and validation of the Birmingham Vasculitis Activity Score (version 3)

Background: Comprehensive multisystem clinical assessment using the Birmingham Vasculitis Activity score (BVAS) is widely used in therapeutic studies of systemic vasculitis. Extensive use suggested a ...
BMJ

Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis

Aim To assess whether overweight and obese patients with psoriatic arthritis (PsA) are less likely to achieve sustained minimal disease activity (MDA) state compared to patients with normal weight.
BMJ

Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke

2 Department of Medicine, Rheumatology Unit, Karolinska Institutet/Karolinska Hospital, Stockholm, Sweden 3 Unit of Clinical Immunology, Uppsala University/Akademiska Sjukhuset, Uppsala, Sweden 4 ...
BMJ

Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults

a Systemic Autoimmune Diseases Unit, Department of Medicine, IDIBAPS , Hospital Clínic, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain, * b Department of Internal Medicine, ...
BMJ

Leflunomide: mode of action in the treatment of rheumatoid arthritis

a Academic Ziekenhuis Leiden, Stafcentrum Reumatologie, Leiden, The Netherlands, b Division of Immunology and Allergy, Geneva University Hospital, Geneva, Switzerland Professor F C Breedveld, Academic ...
BMJ

Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide

Introduction: Potential hepatotoxicity associated with disease-modifying antirheumatic drugs (DMARDs) requires laboratory monitoring. In patients with rheumatoid arthritis (RA) or psoriatic arthritis ...
BMJ

The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 ...

Background: MMP-13 is one of the most important metalloproteases (MMP) involved in osteoarthritis. Licofelone, a novel dual inhibitor of cyclo-oxygenases (COX) and 5-lipoxygenase (5-LOX), can modulate ...
BMJ

Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity

5 Rheumatology Department, H Germans Trias i Pujol, Badalona, Spain 6 Rheumatology Department, H Clinic i Provincial, Barcelona, Spain Correspondence to: Dr L Carmona, Sociedad Española de ...
BMJ

Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III ...

Objective To evaluate ustekinumab efficacy and safety in psoriatic arthritis (PsA) patients with peripheral arthritis and physician-reported spondylitis (termed the ‘spondylitis subset’). Methods ...